Xiaomin Niu

2.3k total citations
88 papers, 1.6k citations indexed

About

Xiaomin Niu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiaomin Niu has authored 88 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 34 papers in Molecular Biology and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiaomin Niu's work include Lung Cancer Treatments and Mutations (28 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Research Studies (11 papers). Xiaomin Niu is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Research Studies (11 papers). Xiaomin Niu collaborates with scholars based in China, United States and France. Xiaomin Niu's co-authors include Shun Lü, Ziming Li, Xiangyun Ye, Shengping Shen, Shun Lu, Yongfeng Yu, Wenxiang Ji, Yunhua Xu, Zhiwei Chen and Weiliang Xia and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Xiaomin Niu

83 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaomin Niu China 25 961 429 422 385 108 88 1.6k
Sheng Liu United States 22 759 0.8× 271 0.6× 343 0.8× 175 0.5× 113 1.0× 65 1.5k
Qian Xie China 27 1.0k 1.1× 412 1.0× 441 1.0× 238 0.6× 211 2.0× 79 2.3k
Beihua Kong China 29 990 1.0× 525 1.2× 523 1.2× 334 0.9× 127 1.2× 99 2.3k
Naimei Tang United States 14 808 0.8× 193 0.4× 180 0.4× 413 1.1× 85 0.8× 26 1.8k
Xi Cheng China 27 816 0.8× 304 0.7× 518 1.2× 266 0.7× 204 1.9× 108 2.0k
Jianghong Deng China 21 1.2k 1.3× 337 0.8× 596 1.4× 182 0.5× 139 1.3× 54 1.9k
Karthikeyan Mythreye United States 25 1.2k 1.2× 343 0.8× 438 1.0× 195 0.5× 107 1.0× 62 2.2k
Baijun Dong China 30 1.3k 1.3× 645 1.5× 378 0.9× 726 1.9× 87 0.8× 90 2.2k
Di Ge China 28 1.4k 1.4× 634 1.5× 539 1.3× 606 1.6× 198 1.8× 114 2.5k
Sang‐Yeob Kim South Korea 24 797 0.8× 262 0.6× 440 1.0× 240 0.6× 128 1.2× 81 1.6k

Countries citing papers authored by Xiaomin Niu

Since Specialization
Citations

This map shows the geographic impact of Xiaomin Niu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaomin Niu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaomin Niu more than expected).

Fields of papers citing papers by Xiaomin Niu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaomin Niu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaomin Niu. The network helps show where Xiaomin Niu may publish in the future.

Co-authorship network of co-authors of Xiaomin Niu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaomin Niu. A scholar is included among the top collaborators of Xiaomin Niu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaomin Niu. Xiaomin Niu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Jian, Hui Wang, Wenqing Lü, et al.. (2025). NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer. Biomarker Research. 13(1). 44–44. 1 indexed citations
3.
Niu, Xiaomin, Qing Tong, Xiaolan Ma, et al.. (2024). Myricetin inhibits 4 T1 breast tumor growth in mice via induction of Nrf-2/GPX4 pathway-mediated Ferroptosis. Toxicology and Applied Pharmacology. 488. 116990–116990. 5 indexed citations
4.
5.
Niu, Xiaomin, et al.. (2024). RPS6KA1 is a histone acetylation-related oncoprotein in acute myeloid leukemia which is targeted by afzelin. BMC Cancer. 24(1). 1189–1189. 2 indexed citations
6.
Ren, Guolian, Xiaohui Zhou, Xiaomin Niu, et al.. (2024). Coassembled Nanoparticles Constructed from Trisulfide Bond-Modified Docetaxel and Hematoporphyrin for Treating 4T1 Breast Tumors. ACS Applied Nano Materials. 7(21). 24729–24741. 1 indexed citations
7.
Yang, Sen, et al.. (2022). Comparison of clinical outcomes and risk factors for COVID-19 infection in cancer patients without anticancer treatment and noncancer patients. Frontiers in Public Health. 10. 925519–925519. 2 indexed citations
8.
Lü, Shun, Jianying Zhou, Xiaomin Niu, et al.. (2021). Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study. Translational Lung Cancer Research. 10(2). 839–854. 8 indexed citations
9.
Niu, Xiaomin, et al.. (2021). Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report. Cancer Treatment and Research Communications. 27. 100345–100345. 1 indexed citations
10.
Jeong, Youngtae, Jessica A. Hellyer, Henning Stehr, et al.. (2019). Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(1). 274–281. 80 indexed citations
11.
Wang, Yonghong, Min Guo, Hui Yang, et al.. (2019). Effect of cisternostomy on prognosis of patients with traumatic brain injury. Zhonghua chuangshang zazhi. 35(5). 389–393. 1 indexed citations
12.
Zhou, Zhen, Yi Zhao, Shengping Shen, et al.. (2019). Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology. 14(8). e157–e159. 28 indexed citations
13.
Niu, Xiaomin, Fatao Liu, Yi Zhou, et al.. (2017). Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment. Clinical Cancer Research. 23(17). 5003–5014. 16 indexed citations
14.
Niu, Xiaomin, et al.. (2017). P1.02-056 Tumor Heterogeneity in Lesion Specific Response Creates ROS1 Fusion Mediating Resistance to Gefitinib in EGFR 19 Deletion Lung Adenocarcinoma. Journal of Thoracic Oncology. 12(1). S521–S522. 1 indexed citations
15.
Sun, Yan, Sha Liu, Zhi Qiao, et al.. (2017). Systematic comparison of exosomal proteomes from human saliva and serum for the detection of lung cancer. Analytica Chimica Acta. 982. 84–95. 120 indexed citations
16.
Niu, Xiaomin, et al.. (2016). PS01.06: Tumor Heterogeneity in Lesion Specific Response Creates ROS1 Fusion Mediating Resistance to Gefitinib in EGFR 19 Deletion Lung Adenocarcinoma. Journal of Thoracic Oncology. 11(11). S273–S273. 2 indexed citations
17.
Tan, Qiang, Jian Cui, Jia Huang, et al.. (2016). Genomic Alteration During Metastasis of Lung Adenocarcinoma. Cellular Physiology and Biochemistry. 38(2). 469–486. 21 indexed citations
18.
Niu, Xiaomin. (2014). Acetylcholine receptor pathway in lung cancer: New twists to an old story. World Journal of Clinical Oncology. 5(4). 667–667. 29 indexed citations
19.
Chen, Zhiwei, Bin Liu, Yunhua Xu, et al.. (2014). FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response. Nucleic Acids Research. 42(18). 11560–11569. 29 indexed citations
20.
Chen, Zhiwei, Xiaomin Niu, Ziming Li, et al.. (2011). Effect of ubiquitin carboxy‐terminal hydrolase 37 on apoptotic in A549 cells. Cell Biochemistry and Function. 29(2). 142–148. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sheng Liu Breakdown of academic impact, for papers by Qian Xie Breakdown of academic impact, for papers by Beihua Kong Breakdown of academic impact, for papers by Naimei Tang Breakdown of academic impact, for papers by Xi Cheng Breakdown of academic impact, for papers by Jianghong Deng Breakdown of academic impact, for papers by Karthikeyan Mythreye Breakdown of academic impact, for papers by Baijun Dong Breakdown of academic impact, for papers by Di Ge Breakdown of academic impact, for papers by Sang‐Yeob Kim
Rankless by CCL
2026